Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | MAOA | P21397 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 2-Aminopyridine SCHEMBL7210909 | 0.85 | RAB9A (0.49) | ALDH1A1MEN1KMT2AHSD17B10TSHR | |
| SCHEMBL263628 | 0.81 | TSHR (0.52) | ALDH1A1MEN1KMT2AHSD17B10TSHR | |
| SCHEMBL1192752 | 0.80 | ALDH1A1 (0.45) | ALDH1A1MEN1KMT2AHSD17B10TSHR | |
| SCHEMBL3376695 | 0.80 | KDM4E (0.51) | ALDH1A1MEN1KMT2AHSD17B10TSHR | |
| SCHEMBL2147241 | 0.80 | KMT2A (0.50) | ALDH1A1MEN1KMT2AHSD17B10TSHR | |
| SCHEMBL161443 | 0.80 | KMT2A (0.50) | ALDH1A1MEN1KMT2AHSD17B10TSHR | |
| SCHEMBL2794458 | 0.79 | TSHR (0.50) | ALDH1A1HSD17B10TSHRKDM4EHPGD | |
| SCHEMBL10389063 | 0.79 | ALDH1A1 (0.47) | ALDH1A1MEN1KMT2AHSD17B10TSHR | |
| SCHEMBL23824155 | 0.79 | KMT2A (0.49) | ALDH1A1MEN1KMT2ATSHRKDM4E | |
| SCHEMBL3356162 | 0.79 | KMT2A (0.49) | ALDH1A1MEN1KMT2AHSD17B10TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1044 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116120324-A | Preparation method of purified allopurinol | 宜兴市星宇药业有限公司 | 2023-05-16 | — | — | CN | claimed |
| CN-114907315-A | Synthesis method of Selitrectinib intermediate | 重庆医科大学 | 2022-08-16 | — | — | CN | claimed |
| US-6846525-B2 | Recording sheets containing purine, pyrimidine, benzimidazole, imidazolidine, urazole, pyrazole, triazole, benzotriazole, tetrazole, and pyrazine compounds | XEROX CORPORATION (US) | 2005-01-25 | — | — | US | claimed |
| US-20040202825-A1 | RECORDING SHEETS CONTAINING PURINE, PYRIMIDINE, BENZIMIDAZOLE, IMIDAZOLIDINE, URAZOLE, PYRAZOLE, TRIAZOLE, BENZOTRIAZOLE, TETRAZOLE, AND PYRAZINE COMPOUNDS | XEROX CORPORATION | 2004-10-14 | — | — | US | claimed |
| EP-0743574-B1 | Migration imaging members | XEROX CORP (US) | 2000-12-27 | — | — | EP | claimed |
| EP-0743573-B1 | Method for obtaining image contrast migration imaging members | XEROX CORP (US) | 2000-09-06 | — | — | EP | claimed |
| US-6106599-A | Inks | XEROX CORPORATION (US) | 2000-08-22 | — | — | US | claimed |
| EP-0673783-B1 | Recording sheets containing purine, pyrimidine, benzimidazole, imidazolidine, urazole, pyrazole, triazole, benzotriazole, tetrazole, and pyrazine compounds | XEROX CORP (US) | 2000-07-05 | — | — | EP | claimed |
| US-5659348-A | APPLYING TO A SUBSTRATE | XEROX CORPORATION (US) | 1997-08-19 | — | — | US | claimed |
| EP-0743574-A2 | Migration imaging members | XEROX CORPORATION (US) | 1996-11-20 | — | — | EP | claimed |
| EP-0743573-A2 | Method for obtaining image contrast migration imaging members | XEROX CORPORATION (US) | 1996-11-20 | — | — | EP | claimed |
| US-5563014-A | SOFTENABLE LAYER CONTAINIG PHOTOSENSITIVE MARKING MATERIAL; TRANSPARENTIZING AGENT | XEROX CORPORATION (US) | 1996-10-08 | — | — | US | claimed |
| US-5514505-A | SELECTIVE TRANSPARENTIZATION OF PHOTOSENSITIVE MIGRATION MARKING PARTICLES EMBEDDED NEAR THE SURFACE OF A SOFTENABLE LAYER SUPPORTED BY AN ELECTROCONDUCTIVE SUBSTRATE | XEROX CORPORATION (US) | 1996-05-07 | — | — | US | claimed |
| EP-0673783-A2 | Recording sheets containing purine, pyrimidine, benzimidazole, imidazolidine, urazole, pyrazole, triazole, benzotriazole, tetrazole, and pyrazine compounds | XEROX CORPORATION (US) | 1995-09-27 | — | — | EP | claimed |
| CN-122094678-A | AP 2-related kinase 1 inhibitors and uses thereof | — | 2026-05-26 | — | — | CN | disclosed |
| WO-2026107328-A1 | AGONISTS OF PARATHYROID HORMONE 1 AND INCRETIN RECEPTORS | SEPTERNA, INC. (US) | 2026-05-21 | — | — | WO | disclosed |
| US-20260014125-A1 | BICYCLIC-TYPE MAT2A INHIBITOR AND USE THEREOF | HAIHE BIOPHARMA CO LTD (CN) | 2026-01-15 | — | — | US | disclosed |
| EP-0001264-A1 | Substituted N-methylene derivatives of thienamycin sulfoxide and sulfone and their preparation | MERCK & CO. INC. (US) | 1979-04-04 | — | — | EP | disclosed |
| US-4093617-A | ENZYME INHIBITORS | ICN PHARMACEUTICALS, INC. (US) | 1978-06-06 | — | — | US | disclosed |
| US-4006127-A | Cationic diazacyanine dyestuffs | BAYER AKTIENGESELLSCHAFT (DT) | 1977-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260014125-A1 | BICYCLIC-TYPE MAT2A INHIBITOR AND USE THEREOF | MAT2A, MNAT1, MAT1A | ALDH1A1 907/4885MEN1 589/4885KMT2A 124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.